Gastrointestinal Cancer

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

By

A clinical trial found a potential marker to identify the patients with advanced esophageal squamous cell carcinoma who were most likely to respond to nivolumab.

<i>HER2</i> Amplification in Brain Metastases May Be Relatively Common in GI Cancer

HER2 Amplification in Brain Metastases May Be Relatively Common in GI Cancer

By

Brain metastases were HER2-positive in nearly one-third of patients with gastrointestinal primary malignancies, suggesting molecular testing may be prudent.

Patient Evaluation of Quality in GI Cancer Surgery

Patient Evaluation of Quality in GI Cancer Surgery

By

Patient-reported quality measures, collected from those who underwent surgery for GI cancer, offered clinicians valuable insight into care management.

Long-Term Surgical Outcomes for Rectal Cancer Survivors Elucidated in Study

Long-Term Surgical Outcomes for Rectal Cancer Survivors Elucidated in Study

By

Participant characteristics were similar between surgical treatment groups.

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

By

In patients who developed CRC, those who had familial CRC type X were found to have worse survival outcomes than those who had Lynch syndrome.

<i>BRCA1</i> Mutation Observed to Confer Heightened Risk of Colorectal Cancer

BRCA1 Mutation Observed to Confer Heightened Risk of Colorectal Cancer

By

A systematic review and meta-analysis determined that carriers for a mutation to BRCA1, but not BRCA2, have an increased risk of colorectal cancer.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Gastric Cancer Treatment Regimens

Get the most up-to-date drug regimens for treating gastric cancer, including treatments such as cisplatin, oxaliplatin, and 5-FU.

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

By

The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

By

Both the reference product and its biosimilar confer to same benefit, according to research results.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes

Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes

By

Stool burden can be a particularly challenging aspect of colonoscopies, making potentially cancerous lesions easier to miss.

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

By

Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.

Evaluation of Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS) evaluation chart based on Manning Criteria and Rome III Diagnostic Criteria.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Rectal Cancer Treatment Regimens

Get the latest treatment options for rectal cancer, including concurrent chemotherapy and radiotherapy and levoleucovorin plus 5-FU.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Antiemetic Medications

A list of drugs used for the treatment of nausea. The chart includes the formulations, strengths, and usual doses for each antiemetic drug product.

Tailoring fecal immunochemical tests positivity thresholds by age and sex may help to optimize colorectal cancer screening

FIT directly measure human hemoglobin concentrations in the stool commonly and are commonly used for colorectal cancer screening.

FDA-Approved Colorectal Cancer Drug Treatments

Colorectal cancer treatment regimen chart.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Fruquintinib increases overall survival in metastatic colorectal carcinoma

Biological agents that target VEGF or EGFR are often used in conjunction with other chemotherapies to treat metastatic colorectal carcinoma (CRC).

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

By

The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs